Skip to content

Study · Systematic review · 2016

10 results

Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.

Xue X, Ren Z, Zhang A, Yang Q, Zhang W, Liu F

International journal of clinical practice25 Jul 2016Cited by 14 (Europe PMC)

PMID27456750 (opens in a new tab)DOI10.1111/ijcp.12847 (opens in a new tab)PepBankPUB-27456750
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in type 2 diabetes, liraglutide was as effective as dulaglutide in controlling glycaemia.

    In plain wordsIn a review of trials in type 2 diabetes, liraglutide controlled blood sugar about as well as dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeGlycaemic control versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide once-weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide was as effective as dulaglutide and more effective than exenatide-LAR and albiglutide in controlling glycaemia.
    2 context sentences
    Summary · context
    The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included.
    Summary · context
    Our analysis included eight trials involving 5531 patients.
  2. 02HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in type 2 diabetes, liraglutide was more effective than exenatide-LAR in controlling glycaemia.

    In plain wordsIn a review of trials in type 2 diabetes, liraglutide controlled blood sugar better than exenatide-LAR.

    Peptide
    Liraglutide
    Outcome
    IncreaseGlycaemic control versus exenatide-LAR
    Study

    n: not reported in source

    Comparator
    Exenatide-LAR once-weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide was as effective as dulaglutide and more effective than exenatide-LAR and albiglutide in controlling glycaemia.
    2 context sentences
    Summary · context
    The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included.
    Summary · context
    Our analysis included eight trials involving 5531 patients.
  3. 03HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in type 2 diabetes, liraglutide was more effective than albiglutide in controlling glycaemia.

    In plain wordsIn a review of trials in type 2 diabetes, liraglutide controlled blood sugar better than albiglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseGlycaemic control versus albiglutide
    Study

    n: not reported in source

    Comparator
    Albiglutide once-weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide was as effective as dulaglutide and more effective than exenatide-LAR and albiglutide in controlling glycaemia.
    2 context sentences
    Summary · context
    The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included.
    Summary · context
    Our analysis included eight trials involving 5531 patients.
  4. 04HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in type 2 diabetes, liraglutide decreased body weight more than exenatide-LAR.

    In plain wordsIn a review of trials in type 2 diabetes, liraglutide reduced weight more than exenatide-LAR.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight decrease versus exenatide-LAR
    Study

    n: not reported in source

    Comparator
    Exenatide-LAR once-weekly
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    With regard to the effectiveness in decreasing body weight, exenatide-LAR, dulaglutide and taspoglutide were similar to exenatide whereas exenatide-LAR, dulaglutide and albiglutide were inferior to liraglutide.
    2 context sentences
    Summary · context
    The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included.
    Summary · context
    Our analysis included eight trials involving 5531 patients.
  5. 05HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in type 2 diabetes, liraglutide decreased body weight more than dulaglutide.

    In plain wordsIn a review of trials in type 2 diabetes, liraglutide reduced weight more than dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight decrease versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide once-weekly
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    With regard to the effectiveness in decreasing body weight, exenatide-LAR, dulaglutide and taspoglutide were similar to exenatide whereas exenatide-LAR, dulaglutide and albiglutide were inferior to liraglutide.
    2 context sentences
    Summary · context
    The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included.
    Summary · context
    Our analysis included eight trials involving 5531 patients.
  6. 06HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in type 2 diabetes, liraglutide decreased body weight more than albiglutide.

    In plain wordsIn a review of trials in type 2 diabetes, liraglutide reduced weight more than albiglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight decrease versus albiglutide
    Study

    n: not reported in source

    Comparator
    Albiglutide once-weekly
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    With regard to the effectiveness in decreasing body weight, exenatide-LAR, dulaglutide and taspoglutide were similar to exenatide whereas exenatide-LAR, dulaglutide and albiglutide were inferior to liraglutide.
    2 context sentences
    Summary · context
    The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included.
    Summary · context
    Our analysis included eight trials involving 5531 patients.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In a systematic review of trials in type 2 diabetes, once-weekly GLP-1 receptor agonists, exenatide and liraglutide had a similar incidence of hypoglycaemia.

    In plain wordsIn a review of trials in type 2 diabetes, once-weekly GLP-1 drugs, exenatide and liraglutide had similar rates of low blood sugar.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncidence of hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Once-weekly GLP-1RAs versus exenatide and liraglutide
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Once-weekly GLP-1RAs, exenatide and liraglutide resulted in a similar incidence of hypoglycaemia and of gastrointestinal, serious, or other AEs.
    2 context sentences
    Summary · context
    The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included.
    Summary · context
    Our analysis included eight trials involving 5531 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 08HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In a systematic review of trials in type 2 diabetes, once-weekly GLP-1 receptor agonists, exenatide and liraglutide had a similar incidence of gastrointestinal adverse events.

    In plain wordsIn a review of trials in type 2 diabetes, once-weekly GLP-1 drugs, exenatide and liraglutide had similar rates of stomach and bowel side effects.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncidence of gastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Once-weekly GLP-1RAs versus exenatide and liraglutide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Once-weekly GLP-1RAs, exenatide and liraglutide resulted in a similar incidence of hypoglycaemia and of gastrointestinal, serious, or other AEs.
    2 context sentences
    Summary · context
    The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included.
    Summary · context
    Our analysis included eight trials involving 5531 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 09HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In a systematic review of trials in type 2 diabetes, once-weekly GLP-1 receptor agonists, exenatide and liraglutide had a similar incidence of serious adverse events.

    In plain wordsIn a review of trials in type 2 diabetes, once-weekly GLP-1 drugs, exenatide and liraglutide had similar rates of serious side effects.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncidence of serious adverse events
    Study

    n: not reported in source

    Comparator
    Once-weekly GLP-1RAs versus exenatide and liraglutide
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Once-weekly GLP-1RAs, exenatide and liraglutide resulted in a similar incidence of hypoglycaemia and of gastrointestinal, serious, or other AEs.
    2 context sentences
    Summary · context
    The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included.
    Summary · context
    Our analysis included eight trials involving 5531 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 10HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In a systematic review of trials in type 2 diabetes, once-weekly GLP-1 receptor agonists, exenatide and liraglutide had a similar incidence of other adverse events.

    In plain wordsIn a review of trials in type 2 diabetes, once-weekly GLP-1 drugs, exenatide and liraglutide had similar rates of other side effects.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncidence of other adverse events
    Study

    n: not reported in source

    Comparator
    Once-weekly GLP-1RAs versus exenatide and liraglutide
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Once-weekly GLP-1RAs, exenatide and liraglutide resulted in a similar incidence of hypoglycaemia and of gastrointestinal, serious, or other AEs.
    2 context sentences
    Summary · context
    The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included.
    Summary · context
    Our analysis included eight trials involving 5531 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.